Tags

Type your tag names separated by a space and hit enter

Two tissue-resident progenitor lineages drive distinct phenotypes of heterotopic ossification.
Sci Transl Med. 2016 11 23; 8(366):366ra163.ST

Abstract

Fibrodysplasia ossificans progressiva (FOP), a congenital heterotopic ossification (HO) syndrome caused by gain-of-function mutations of bone morphogenetic protein (BMP) type I receptor ACVR1, manifests with progressive ossification of skeletal muscles, tendons, ligaments, and joints. In this disease, HO can occur in discrete flares, often triggered by injury or inflammation, or may progress incrementally without identified triggers. Mice harboring an Acvr1R206H knock-in allele recapitulate the phenotypic spectrum of FOP, including injury-responsive intramuscular HO and spontaneous articular, tendon, and ligament ossification. The cells that drive HO in these diverse tissues can be compartmentalized into two lineages: an Scx+ tendon-derived progenitor that mediates endochondral HO of ligaments and joints without exogenous injury, and a muscle-resident interstitial Mx1+ population that mediates intramuscular, injury-dependent endochondral HO. Expression of Acvr1R206H in either lineage confers aberrant gain of BMP signaling and chondrogenic differentiation in response to activin A and gives rise to mutation-expressing hypertrophic chondrocytes in HO lesions. Compared to Acvr1R206H, expression of the man-made, ligand-independent ACVR1Q207D mutation accelerates and increases the penetrance of all observed phenotypes, but does not abrogate the need for antecedent injury in muscle HO, demonstrating the need for an injury factor in addition to enhanced BMP signaling. Both injury-dependent intramuscular and spontaneous ligament HO in Acvr1R206H knock-in mice were effectively controlled by the selective ACVR1 inhibitor LDN-212854. Thus, diverse phenotypes of HO found in FOP are rooted in cell-autonomous effects of dysregulated ACVR1 signaling in nonoverlapping tissue-resident progenitor pools that may be addressed by systemic therapy or by modulating injury-mediated factors involved in their local recruitment.

Authors+Show Affiliations

Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA.Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA.Regeneron Pharmaceuticals Inc., 777 Old Saw Mill River Road, Tarrytown, NY 10591, USA.Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA.Regeneron Pharmaceuticals Inc., 777 Old Saw Mill River Road, Tarrytown, NY 10591, USA.Division of Rheumatology, Immunology, and Allergy, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA.Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA.Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA.National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD 20850, USA.Departments of Internal Medicine, Endocrine Section, and Epidemiology and Biostatistics, VU University Medical Center, PO Box 7057, Amsterdam 1007 MB, Netherlands.Departments of Internal Medicine, Endocrine Section, and Epidemiology and Biostatistics, VU University Medical Center, PO Box 7057, Amsterdam 1007 MB, Netherlands.Endocrine Unit, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, Boston, MA 02114, USA.Children's Cancer Therapy Development Institute, 12655 SW Beaverdam Road-West, Beaverton, OR 97005, USA.Department of Stem Cell and Regenerative Biology, Harvard University and Harvard Stem Cell Institute, Cambridge, MA 02138, USA. Joslin Diabetes Center, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA.Regeneron Pharmaceuticals Inc., 777 Old Saw Mill River Road, Tarrytown, NY 10591, USA. Regeneron Genetics Center, Tarrytown, NY 10591, USA.Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA. pbyu@partners.org.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

27881824

Citation

Dey, Devaveena, et al. "Two Tissue-resident Progenitor Lineages Drive Distinct Phenotypes of Heterotopic Ossification." Science Translational Medicine, vol. 8, no. 366, 2016, pp. 366ra163.
Dey D, Bagarova J, Hatsell SJ, et al. Two tissue-resident progenitor lineages drive distinct phenotypes of heterotopic ossification. Sci Transl Med. 2016;8(366):366ra163.
Dey, D., Bagarova, J., Hatsell, S. J., Armstrong, K. A., Huang, L., Ermann, J., Vonner, A. J., Shen, Y., Mohedas, A. H., Lee, A., Eekhoff, E. M., van Schie, A., Demay, M. B., Keller, C., Wagers, A. J., Economides, A. N., & Yu, P. B. (2016). Two tissue-resident progenitor lineages drive distinct phenotypes of heterotopic ossification. Science Translational Medicine, 8(366), 366ra163.
Dey D, et al. Two Tissue-resident Progenitor Lineages Drive Distinct Phenotypes of Heterotopic Ossification. Sci Transl Med. 2016 11 23;8(366):366ra163. PubMed PMID: 27881824.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Two tissue-resident progenitor lineages drive distinct phenotypes of heterotopic ossification. AU - Dey,Devaveena, AU - Bagarova,Jana, AU - Hatsell,Sarah J, AU - Armstrong,Kelli A, AU - Huang,Lily, AU - Ermann,Joerg, AU - Vonner,Ashley J, AU - Shen,Yue, AU - Mohedas,Agustin H, AU - Lee,Arthur, AU - Eekhoff,Elisabeth M W, AU - van Schie,Annelies, AU - Demay,Marie B, AU - Keller,Charles, AU - Wagers,Amy J, AU - Economides,Aris N, AU - Yu,Paul B, PY - 2015/04/28/received PY - 2016/09/23/accepted PY - 2016/11/25/entrez PY - 2016/11/25/pubmed PY - 2017/12/30/medline SP - 366ra163 EP - 366ra163 JF - Science translational medicine JO - Sci Transl Med VL - 8 IS - 366 N2 - Fibrodysplasia ossificans progressiva (FOP), a congenital heterotopic ossification (HO) syndrome caused by gain-of-function mutations of bone morphogenetic protein (BMP) type I receptor ACVR1, manifests with progressive ossification of skeletal muscles, tendons, ligaments, and joints. In this disease, HO can occur in discrete flares, often triggered by injury or inflammation, or may progress incrementally without identified triggers. Mice harboring an Acvr1R206H knock-in allele recapitulate the phenotypic spectrum of FOP, including injury-responsive intramuscular HO and spontaneous articular, tendon, and ligament ossification. The cells that drive HO in these diverse tissues can be compartmentalized into two lineages: an Scx+ tendon-derived progenitor that mediates endochondral HO of ligaments and joints without exogenous injury, and a muscle-resident interstitial Mx1+ population that mediates intramuscular, injury-dependent endochondral HO. Expression of Acvr1R206H in either lineage confers aberrant gain of BMP signaling and chondrogenic differentiation in response to activin A and gives rise to mutation-expressing hypertrophic chondrocytes in HO lesions. Compared to Acvr1R206H, expression of the man-made, ligand-independent ACVR1Q207D mutation accelerates and increases the penetrance of all observed phenotypes, but does not abrogate the need for antecedent injury in muscle HO, demonstrating the need for an injury factor in addition to enhanced BMP signaling. Both injury-dependent intramuscular and spontaneous ligament HO in Acvr1R206H knock-in mice were effectively controlled by the selective ACVR1 inhibitor LDN-212854. Thus, diverse phenotypes of HO found in FOP are rooted in cell-autonomous effects of dysregulated ACVR1 signaling in nonoverlapping tissue-resident progenitor pools that may be addressed by systemic therapy or by modulating injury-mediated factors involved in their local recruitment. SN - 1946-6242 UR - https://www.unboundmedicine.com/medline/citation/27881824/Two_tissue_resident_progenitor_lineages_drive_distinct_phenotypes_of_heterotopic_ossification_ L2 - http://stm.sciencemag.org/cgi/pmidlookup?view=short&pmid=27881824 DB - PRIME DP - Unbound Medicine ER -